Minimal Residual Disease

Achievement of minimal residual disease negativity appeared associated with superior DFS and OS among patients with acute myeloid leukemia, according to results of a meta-analysis published in JAMA Oncology.

Minimal residual disease persistence prior to allogeneic hematopoietic stem cell transplant influenced OS and RFS among patients with acute leukemia, according to study results presented at Society of Hematologic Oncology Annual Meeting.

An antimetabolite-based regimen with low myelosuppressive activity may be capable of eradicating a subset of pediatric B-cell acute lymphoblastic leukemia, according to results of a prospective study published in Blood.

ORLANDO — A chemotherapy-free, triplet combination regimen of umbralisib, ublituximab and venetoclax was well-tolerated and achieved high rates of undetectable minimal residual disease after 12 cycles of therapy among patients with relapsed or refractory chronic lymphocytic leukemia, according to preliminary results of a phase 1/2 trial presented at ASH Annual Meeting and Exposition.

ORLANDO — A novel triple-agent combination of carfilzomib, dexamethasone and daratumumab outperformed carfilzomib plus dexamethasone in terms of PFS and overall response rate among patients with relapsed or refractory multiple myeloma, according to results of the randomized phase 3 CANDOR trial presented during the late-breaking abstract session of ASH Annual Meeting and Exposition.

ORLANDO — Achieving complete remission and minimal residual disease negativity appeared to be independently associated with reduced cumulative incidence of relapse and longer RFS among patients with relapsed or refractory acute myeloid leukemia receiving initial salvage therapy, according to results of a retrospective study presented at ASH Annual Meeting and Exposition.

ORLANDO — An all-oral combination of venetoclax plus ibrutinib in the frontline setting was well tolerated and associated with high rates of undetectable minimal residual disease in the blood and bone marrow of patients with chronic lymphocytic leukemia after 1 year of therapy, according to results of the phase 2 CAPTIVATE trial presented at the ASH Annual Meeting and Exposition.